AstraZeneca Reports Detailed Results of Farxiga (dapagliflozin) in P-III DAPA-HF Study to Treat Patients with Heart Failure

 AstraZeneca Reports Detailed Results of Farxiga (dapagliflozin) in P-III DAPA-HF Study to Treat Patients with Heart Failure

AstraZeneca Reports Detailed Results of Farxiga (dapagliflozin) in P-III DAPA-HF Study to Treat Patients with Heart Failure

Shots:

  • The P-III DAPA-HF study involves assessing of Farxiga (10mg) vs PBO in addition to SOC in patients with HF and reduced ejection fraction (LVEF ≤ 40%) with/out T2D
  • The P-III DAPA-HF study results: 26% reduction in CV death or worsening of HF; 30% reduction in risk of experiencing a first episode of worsening HF; 18% reduction in risk of CV deaths; improvement in patients measured by KCCQ total symptom score (7.9 vs 9.5 with an event/100 patient-yrs.); patients with volume depletion (7.5% vs 6.8%); renal AEs (6.5% vs 7.2%)
  • Farxiga (qd) is an oral SGLT2 inhibitor indicated both as a monothx. and combination therapy to improve glycemic control, with weight loss and reduction in BP, as an adjunct to diet and exercise in adults with T2D

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Chicago Tribune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post